Novo Nordisk Faces a Crucial Crossroads: Generics, Pipeline Wins, and a Pivotal Earnings Report

Novo Nordisk enters a pivotal week with Canada approving first Ozempic generics, oral Ozempic exceeding prescription expectations, and promising rare-disease trial data offsetting GLP-1 headwinds.

The Danish pharmaceutical giant enters one of its most consequential weeks in years, with a generics breakthrough in Canada, promising clinical data from its rare-disease pipeline, and first-quarter earnings all converging on the same calendar. The confluence of events will test whether Novo Nordisk can navigate mounting headwinds in its core GLP-1 business while proving its long-term growth story remains intact.

Canada Breaks Ground on Ozempic Generics

Health Canada approved the first generic version of semaglutide on April 28, 2026, granting authorization to India’s Dr. Reddy’s Laboratories. Just three days later, a second generic from Canadian manufacturer Apotex followed. Both products target Type-2 diabetes in adults, marking the first time a G7 nation has opened the door to copycat versions of Novo’s blockbuster drug.

The implications extend far beyond Canada’s borders. Dr. Reddy’s described the country as the world’s second-largest semaglutide market and signaled plans for a global rollout. Health Canada is currently reviewing eight additional generic applications from other manufacturers. Under the country’s pricing framework, the first generic enters at 75 to 85 percent of the original price. A second entrant pushes both products down to 50 percent, and three or more generics slash the price to roughly 35 percent of Ozempic’s current level.

Regulatory reviews are also underway in Brazil and China, where patents expired in March. Novo Nordisk had previously guided for a mid-single-digit percentage negative impact on international sales from generic competition.

Oral Ozempic Launch Exceeds Early Expectations

Against this backdrop of pricing pressure, Novo launched oral Ozempic in the United States on May 4 — the only FDA-approved oral GLP-1 for Type-2 diabetes. The rollout reached more than 70,000 pharmacies nationwide.

Early prescription data surprised analysts. Eli Lilly’s newly approved oral pill Foundayo recorded roughly 3,700 prescriptions in its second week on the market. Novo’s oral offering logged over 18,000 prescriptions in a comparable period — a ratio few on Wall Street anticipated, given Lilly’s better-funded launch campaign.

Novo also claimed that its oral Wegovy variant delivered significantly greater weight loss than Foundayo in a cross-trial analysis of published studies. The discontinuation rate due to side effects was approximately 14 times higher for Lilly’s drug in that comparison.

Rare-Disease Pipeline Delivers Surprise Strength

While the GLP-1 franchise faces mounting challenges, Novo’s work in rare diseases is generating fresh optimism. Recent trial data for Denecimig, a treatment for Hemophilia A, showed a 99 percent reduction in bleeding rates compared to on-demand therapy. The FDA has been reviewing a corresponding approval application since last autumn.

In sickle cell disease, the orally administered Etavopivat reduced painful vaso-occlusive crises by 27 percent in the pivotal HIBISCUS study. Novo plans to file for approval in the second half of 2026, and analysts see potential peak sales in the billions if the drug reaches the market.

Earnings Preview: Expectations Are Subdued

Novo Nordisk reports first-quarter results on May 6 at 7:30 AM CET, followed by a conference call at 1:00 PM. Analysts project an 8 percent revenue decline year-over-year and a 16 percent drop in earnings per share. The company’s full-year guidance calls for a 5 to 13 percent decline in adjusted sales, a range that will face scrutiny given the Canadian generic developments.

The report will be the first to include revenue contributions from the oral Wegovy launch and the first where management must formally address the Canadian generic situation. Citi recently downgraded the stock, while Bernstein initiated coverage with an “underperform” rating. More optimistic voices point to a projected free cash flow yield above 6.5 percent for 2027 and a dividend yield of roughly 4 percent as support for the share price.

Novo recently completed a 3.44 billion Danish krone share buyback program, part of a larger 15 billion krone authorization intended to provide a valuation buffer. The stock has recovered modestly to near $44, though it remains well below its all-time highs.

The coming days will reveal whether Novo’s pipeline promise and early oral GLP-1 traction can offset the structural pressures reshaping its core business.